These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33561390)

  • 21. MeCP2 dysfunction in Rett syndrome and related disorders.
    Moretti P; Zoghbi HY
    Curr Opin Genet Dev; 2006 Jun; 16(3):276-81. PubMed ID: 16647848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice.
    Heckman LD; Chahrour MH; Zoghbi HY
    Elife; 2014 Jun; 3():. PubMed ID: 24970834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research.
    Zachariah RM; Rastegar M
    Neural Plast; 2012; 2012():415825. PubMed ID: 22474603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome.
    Robinson L; Guy J; McKay L; Brockett E; Spike RC; Selfridge J; De Sousa D; Merusi C; Riedel G; Bird A; Cobb SR
    Brain; 2012 Sep; 135(Pt 9):2699-710. PubMed ID: 22525157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MeCP2, A Modulator of Neuronal Chromatin Organization Involved in Rett Syndrome.
    Martínez de Paz A; Ausió J
    Adv Exp Med Biol; 2017; 978():3-21. PubMed ID: 28523538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The molecular pathology of Rett syndrome: synopsis and update.
    Akbarian S; Jiang Y; Laforet G
    Neuromolecular Med; 2006; 8(4):485-94. PubMed ID: 17028371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis.
    Forlani G; Giarda E; Ala U; Di Cunto F; Salani M; Tupler R; Kilstrup-Nielsen C; Landsberger N
    Hum Mol Genet; 2010 Aug; 19(16):3114-23. PubMed ID: 20504995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative analysis questions the role of MeCP2 as a global regulator of alternative splicing.
    Chhatbar K; Cholewa-Waclaw J; Shah R; Bird A; Sanguinetti G
    PLoS Genet; 2020 Oct; 16(10):e1009087. PubMed ID: 33048927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for the ability of MBD domains to bind methyl-CG and TG sites in DNA.
    Liu K; Xu C; Lei M; Yang A; Loppnau P; Hughes TR; Min J
    J Biol Chem; 2018 May; 293(19):7344-7354. PubMed ID: 29567833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MECP2, a multi-talented modulator of chromatin architecture.
    Della Ragione F; Vacca M; Fioriniello S; Pepe G; D'Esposito M
    Brief Funct Genomics; 2016 Nov; 15(6):420-431. PubMed ID: 27296483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence: new perspective for Rett syndrome.
    Squillaro T; Alessio N; Cipollaro M; Melone MA; Hayek G; Renieri A; Giordano A; Galderisi U
    Mol Biol Cell; 2012 Apr; 23(8):1435-45. PubMed ID: 22357617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of MeCP2 in CNS development and function.
    Na ES; Monteggia LM
    Horm Behav; 2011 Mar; 59(3):364-8. PubMed ID: 20515694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model.
    Viola A; Saywell V; Villard L; Cozzone PJ; Lutz NW
    PLoS One; 2007 Jan; 2(1):e157. PubMed ID: 17237885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Mecp2
    Gandaglia A; Brivio E; Carli S; Palmieri M; Bedogni F; Stefanelli G; Bergo A; Leva B; Cattaneo C; Pizzamiglio L; Cicerone M; Bianchi V; Kilstrup-Nielsen C; D'Annessa I; Di Marino D; D'Adamo P; Antonucci F; Frasca A; Landsberger N
    Mol Neurobiol; 2019 Jul; 56(7):4838-4854. PubMed ID: 30402709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome.
    Peddada S; Yasui DH; LaSalle JM
    Hum Mol Genet; 2006 Jun; 15(12):2003-14. PubMed ID: 16682435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequence-specific DNA binding by AT-hook motifs in MeCP2.
    Lyst MJ; Connelly J; Merusi C; Bird A
    FEBS Lett; 2016 Sep; 590(17):2927-33. PubMed ID: 27461740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MECP2 disorders: from the clinic to mice and back.
    Lombardi LM; Baker SA; Zoghbi HY
    J Clin Invest; 2015 Aug; 125(8):2914-23. PubMed ID: 26237041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains.
    Itoh M; Ide S; Takashima S; Kudo S; Nomura Y; Segawa M; Kubota T; Mori H; Tanaka S; Horie H; Tanabe Y; Goto Y
    J Neuropathol Exp Neurol; 2007 Feb; 66(2):117-23. PubMed ID: 17278996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methyl-CpG-binding protein 2 mediates overlapping mechanisms across brain disorders.
    Bach S; Ryan NM; Guasoni P; Corvin AP; El-Nemr RA; Khan D; Sanfeliu A; Tropea D
    Sci Rep; 2020 Dec; 10(1):22255. PubMed ID: 33335218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation mechanism and research progress of MeCP2 in Rett syndrome.
    Yang W; Pan H
    Yi Chuan; 2014 Jul; 36(7):625-30. PubMed ID: 25076025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.